Biotechnology leader Moderna announced on November 16 that its COVID-19 vaccine candidate achieved 94.5% efficacy. This follows closely on Pfizer and BioNTech's recent disclosure of 90% effectiveness.
With over 100 vaccines in development worldwide, only a handful have reached phase 3 trials—the critical final stage before seeking regulatory approval. Pfizer's collaboration with BioNTech highlighted strong interim results, paving the way for Moderna's announcement.
Caution remains essential. These early findings don't fully confirm prevention of severe or fatal cases, asymptomatic infections, or long-term side effects. Peer-reviewed data and full trial completion are still pending.
Yet, the news has sparked global optimism, signaling a potential turning point in the pandemic. Both announcements drove significant market gains for the companies involved.
Moderna, building on promising phase 1 data, reported that its vaccine reduced COVID-19 risk by 94.5%. In the trial, 90 placebo participants contracted the virus, versus just five in the vaccinated group.
Critically, no severe COVID-19 cases occurred among the vaccinated, compared to 11 in the placebo group. Common side effects after the second dose—fatigue, muscle aches, or injection-site redness—affected 9-10% of recipients.
This efficacy rivals top vaccines like measles (97% with two doses), per CDC data.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate,” said Moderna CEO Stéphane Bancel. “This positive interim analysis from our phase 3 trial provides the first clinical evidence that our vaccine can prevent COVID-19, including severe disease.”
These are preliminary results from an ongoing trial with over 30,000 participants since July. Like Pfizer-BioNTech, Moderna plans to seek U.S. emergency use authorization soon, pending full review.
French distribution plans include -80°C storage at pharmacies, with 24-48 hour delivery nationwide. Post-thaw, vaccines can be kept at 2°C to 8°C for up to 5 days. Alternatively, dry ice-insulated boxes enable up to 16 days of storage with limited openings.
